Serum tobramycin levels following delivery of tobramycin (Tobi®) via eFlow® advanced nebuliser in children with cystic fibrosis

被引：8
作者：
Guy, E. L. [1 ]
Bosomworth, M. [2 ]
Denton, M. [3 ]
Conway, S. P. [1 ]
Brownlee, K. G. [1 ]
Lee, T. W. R. [1 ]
机构：
[1] St James Univ Hosp, Leeds Reg Paediat Cyst Fibrosis Ctr, Leeds LS9 7TF, W Yorkshire, England
[2] St James Univ Hosp, Dept Biochem, Leeds LS9 7TF, W Yorkshire, England
[3] St James Univ Hosp, Dept Microbiol, Leeds LS9 7TF, W Yorkshire, England
来源：
JOURNAL OF CYSTIC FIBROSIS | 2010年 / 9卷 / 04期
关键词：
Cystic fibrosis; Paediatric; TOBI; eFlow; Pseudomonas aeruginosa; BETA-D-GLUCOSAMINIDASE; INHALED TOBRAMYCIN; AEROSOLIZED TOBRAMYCIN; YOUNG-CHILDREN; LUNG-DISEASE; INHALATION; PHARMACOKINETICS; ADOLESCENT; SAFETY; RISK;
D O I：
10.1016/j.jcf.2010.03.007
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Background: Safety and toxicity data for nebulised tobramycin are mainly derived from use of the Pani LC (R) Plus nebuliser, yet many centres are now using advanced nebulisers, such as the eFlow (R). Methods: Ten children (ages 2-16 years) receiving 300 mg TOBI (R) via eFlow (R) for clinical reasons participated. Serum tobramycin levels were obtained 1 h post nebulisation. Nine provided samples for urinary NAG, and 10 underwent audiology. Results: Tobramycin levels were >1 mg/L in 3 children (maximum 3.8, 2 children aged 2 years). Urine NAG/creatinine levels were raised (>0.94 mu mol/min/mmol) in 5 children, 1 of these had a tobramycin level of >1 mg/L. One patient had high frequency hearing loss. Conclusion: Serum tobramycin levels over 1 mg/L can occur 1 h post 300 mg TOBI (R) delivered by eFlow (R). Raised urinary NAG levels suggest that some children may have some associated early renal toxicity. (C) 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码：292 / 295
页数：4
相关论文
共 24 条
  • [1] Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use
    Al-Aloul, M
    Miller, H
    Alapati, S
    Stockton, PA
    Ledson, MJ
    Walshaw, MJ
    [J]. PEDIATRIC PULMONOLOGY, 2005, 39 (01) : 15 - 20
  • [2] Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis:: Before, during and after treatment with intravenous antibiotics
    Etherington, C.
    Bosomworth, M.
    Clifton, I.
    Peckham, D. G.
    Conway, S. P.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2007, 6 (01) : 67 - 73
  • [3] Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system
    Geller, DE
    Rosenfeld, M
    Waltz, DA
    Wilmott, RW
    [J]. CHEST, 2003, 123 (01) : 28 - 36
  • [4] Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis
    Geller, DE
    Pitlick, WH
    Nardella, PA
    Tracewell, WG
    Ramsey, BW
    [J]. CHEST, 2002, 122 (01) : 219 - 226
  • [5] Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis
    Gibson, RL
    Emerson, J
    McNamara, S
    Burns, LL
    Rosenfeld, M
    Yunker, A
    Hamblett, N
    Accurso, F
    Dovey, M
    Hiatt, P
    Konstan, MW
    Moss, R
    Retsch-Bogart, G
    Wagener, J
    Waltz, D
    Wilmott, R
    Zeitlin, PL
    Ramsey, B
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (06) : 841 - 849
  • [6] Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus
    Heijerman, Harry
    Westerman, Elsbeth
    Conway, Steven
    Touw, Daan
    Doring, Gerd
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2009, 8 (05) : 295 - 315
  • [7] Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis
    Hubert, Dominique
    Leroy, Sylvie
    Nove-Josserand, Raphaele
    Murris-Espin, Marlene
    Mely, Laurent
    Dominique, Stephane
    Delaisi, Bertrand
    Kho, Pearl
    Kovarik, John M.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2009, 8 (05) : 332 - 337
  • [8] PATHOGENESIS OF CYSTIC-FIBROSIS
    KOCH, C
    HOIBY, N
    [J]. LANCET, 1993, 341 (8852) : 1065 - 1069
  • [9] Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis
    Konstan, Michael W.
    Morgan, Wayne J.
    Butler, Steven M.
    Pasta, David J.
    Craib, Marcia L.
    Silva, Stefanie J.
    Stokes, Dennis C.
    Wohl, Mary Ellen B.
    Wagener, Jeffrey S.
    Regelmann, Warren E.
    Johnson, Charles A.
    [J]. JOURNAL OF PEDIATRICS, 2007, 151 (02) : 134 - 139
  • [10] Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition
    Kosorok, MR
    Zeng, L
    West, SEH
    Rock, MJ
    Splaingard, ML
    Laxova, A
    Green, CG
    Collins, J
    Farrell, PM
    [J]. PEDIATRIC PULMONOLOGY, 2001, 32 (04) : 277 - 287
123